ストックスクリーナーアプリを入手
0.7746
5.29%
0.0356
Affimed N V (AFMD) 最新ニュース
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting | AFMD Stock News - GuruFocus
Affimed Announces Acceptance of Three Abstracts for - GlobeNewswire
Affimed Secures Coveted Oral Presentation Slot at ASCO 2025: Phase 2 Lymphoma and Lung Cancer Data - Stock Titan
Affimed faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Affimed Faces Nasdaq Delisting Risk Due to Share Price - TipRanks
Affimed faces Nasdaq delisting over share price rule - Investing.com Australia
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode - MSN
Affimed (AFMD) Faces Nasdaq Delisting Risk Due to Low Share Price | AFMD Stock News - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Over Share Price - GuruFocus
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | AFMD Stock News - GuruFocus
Affimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Nasdaq
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Affimed Gets 180-Day Nasdaq Grace Period After Stock Falls Below $1, Extension Possible - Stock Titan
Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com - Defense World
Affimed N.V. Receives EUR 2.4 Million Research Grant from German Government to Fund Trispecific Abs - marketscreener.com
Affimed (NASDAQ:AFMD) Now Covered by Analysts at StockNews.com - Defense World
Affimed (NASDAQ:AFMD) Receives $13.50 Average Target Price from Analysts - Defense World
Short Interest in Affimed (NASDAQ:AFMD) Declines By 14.9% - Defense World
Affimed Announces Acceptance of AFM24 Abstract on Dose - GlobeNewswire
Major Cancer Conference to Showcase New AFM24 Drug Optimization Results for Lung Cancer Treatment - Stock Titan
Affimed (AFMD) to Release Earnings on Thursday - Defense World
Affimed at Leerink’s Conference: Clinical and Strategic Insights - Investing.com
Affimed at Leerink’s Conference: Clinical and Strategic Insights By Investing.com - Investing.com UK
Affimed N.V. to Host Earnings Call - ACCESS Newswire
Can Affimed's CEO Presentation Signal New Oncology Breakthroughs? Conference Watch - StockTitan
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Affimed Announces Proposed Public Offering Of Common Stock - Reuters
Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3% - Defense World
Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial - MSN
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Yahoo Finance
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients - Yahoo Finance
0.39%
0.80%
大文字化:
|
ボリューム (24 時間):